FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 282 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... June 12, 2024 Screening People at High Risk for Pancreatic Cancer May Help Them... August 2, 2024 Spotlight On: Pelvic Physical Therapists in Cancer Care March 31, 2021 FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 Load more HOT NEWS The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not... Cancer, COVID-19, and Competing Threats to Indigenous Health Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine
